Opus Genetics (IRD) News Today $1.20 +0.02 (+1.69%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.20 0.00 (0.00%) As of 08/15/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IRD Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Opus Genetics, Inc. (NASDAQ:IRD) Just Reported Earnings, And Analysts Cut Their Target PriceAugust 16 at 10:03 AM | finance.yahoo.comOpus Genetics (NASDAQ:IRD) Issues Earnings ResultsAugust 15 at 11:59 PM | marketbeat.comOpus Genetics, Inc.: Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate UpdateAugust 14 at 11:59 AM | finanznachrichten.deOpus Genetics reports Q2 EPS (12c) vs (30c) last yearAugust 14 at 11:59 AM | msn.comOpus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate UpdateAugust 14 at 11:59 AM | finance.yahoo.comOpus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate UpdateAugust 13 at 4:30 PM | globenewswire.comOpus Genetics (IRD) to Release Earnings on TuesdayAugust 10, 2025 | americanbankingnews.comOpus Genetics (IRD) Expected to Announce Earnings on TuesdayAugust 6, 2025 | marketbeat.comOpus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 5, 2025 | globenewswire.comOpus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood BlindnessJuly 24, 2025 | finance.yahoo.comOpus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood BlindnessJuly 23, 2025 | globenewswire.comOpus Genetics (NASDAQ:IRD) Raised to "Hold" at Wall Street ZenJuly 12, 2025 | marketbeat.comOpus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 5, 2025 | morningstar.comMOpus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comOpus Genetics, Inc. (IRD) Income Statement - Yahoo FinanceJune 30, 2025 | finance.yahoo.comOpus Genetics (NASDAQ:IRD) Stock Rating Lowered by Wall Street ZenJune 28, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Opus Genetics (NASDAQ:IRD)June 27, 2025 | marketbeat.comOpus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaJune 26, 2025 | globenewswire.comOpus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK ProgramJune 23, 2025 | globenewswire.comOpus Genetics (NASDAQ:IRD) Trading 1% Higher - What's Next?June 6, 2025 | marketbeat.comOpus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under ...June 4, 2025 | seekingalpha.comIRD Opus Genetics, Inc.June 3, 2025 | seekingalpha.comOpus Genetics Shares Rise After Positive Trial Results for Eye TreatmentJune 2, 2025 | marketwatch.comOpus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ConditionsJune 2, 2025 | globenewswire.comOpus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 18, 2025 | finance.yahoo.comOpus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate UpdateMay 15, 2025 | globenewswire.comOpus Genetics to Present Advances in Gene Therapy for Inherited Retinal Diseases at Major Scientific Conferences in May 2025May 13, 2025 | nasdaq.comOpus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in MayMay 12, 2025 | globenewswire.comOpus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy CandidateMay 6, 2025 | globenewswire.comOpus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful VisionMay 5, 2025 | globenewswire.comOpus Genetics shareholders approve key proposalsMay 3, 2025 | investing.comPRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George MagrathApril 15, 2025 | markets.businessinsider.comCraig-Hallum Initiates Coverage of Opus Genetics (IRD) with Buy RecommendationApril 12, 2025 | msn.comCraig-Hallum bullish on Opus Genetics, initiates with a BuyApril 11, 2025 | markets.businessinsider.comOpus Genetics initiated with a Buy at Craig-HallumApril 11, 2025 | markets.businessinsider.comFounder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance ConcernsApril 11, 2025 | globenewswire.comOpus Genetics announces data from patient in Phase 1/2 trial of OPGx-LCA5April 8, 2025 | markets.businessinsider.comOpus Genetics urges stockholders to vote for company’s nine board nomineesApril 8, 2025 | markets.businessinsider.comOpus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal DiseasesApril 8, 2025 | globenewswire.comOpus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company’s Transformation and ProgressApril 7, 2025 | markets.businessinsider.comParty Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings ForecastsApril 5, 2025 | finance.yahoo.comOpus Genetics Terminates Purchase Agreement with Lincoln ParkApril 4, 2025 | tipranks.comOpus Genetics price target lowered to $8 from $9 at JonesResearchApril 2, 2025 | markets.businessinsider.comOpus Genetics to Participate in Upcoming Investor Conference in AprilApril 2, 2025 | globenewswire.comOpus Leans Lower on Year-End FiguresMarch 31, 2025 | baystreet.caOpus Genetics reports FY24 EPS ($2.15) vs. (46c) last yearMarch 31, 2025 | markets.businessinsider.comOpus Genetics Announces Financial Results for Full Year 2024March 31, 2025 | globenewswire.comSeveral Insiders Invested In Opus Genetics Flagging Positive NewsMarch 26, 2025 | finance.yahoo.comOpus Genetics presents data on phentolamine ophthalmic solution 0.75%March 22, 2025 | markets.businessinsider.comOpus Genetics prices 21.05M shares at 95c in public offeringMarch 22, 2025 | markets.businessinsider.com Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address IRD Media Mentions By Week IRD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IRD News Sentiment▼0.240.63▲Average Medical News Sentiment IRD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IRD Articles This Week▼92▲IRD Articles Average Week Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mereo BioPharma Group News Tiziana Life Sciences News scPharmaceuticals News Prima BioMed News Alpha Teknova News Alumis News Adherex Technologies News Neumora Therapeutics News Galectin Therapeutics News Puma Biotechnology News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IRD) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access